Introduction In recent years, monoclonal antibodies targeting Type-2 inflammatory pathways
have been developed for severe asthma treatment. However, even when patients are …

The long-term goal of asthma management is to achieve disease control, comprised of the
assessment of two main domains: 1) symptom control and 2) future risk of adverse …

Background Novel biologic therapies have revolutionised the management of severe
asthma with more ambitious treatment aims. Here we analyse the definition of clinical …

Introduction Dupilumab, a fully human anti-interleukin-4/interleukin-13 monoclonal antibody,
has shown efficacy in many aspects of Type-2 severe asthma management. Currently, we …

Introduction Clinical remission (CliR) achievement has been recognized as a new potential
outcome in severe asthma. Nevertheless, we still lack a detailed profile of what features …

Background Asthma remission has emerged as a potential treatment goal. This study
evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving …

Introduction Data on the clinical efficacy and remodeling of omalizumab therapy in patients
on oral corticosteroids (OC) are limited. Objective The purpose of the study is to show that in …

Remission has been included as the treatment goal in asthma in several national
guidelines, reflecting the paradigm shift in asthma, from short-term symptom control to long …

Rationale: There is no consensus on criteria to include in an asthma remission definition in
real-life. Factors associated with achieving remission post-biologic-initiation remain poorly …

Asthma is a common respiratory condition that affects more than 300 million people globally.
It has variable symptoms and severity levels, with about 10% of patients experiencing …